"Neuromuscular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.
Descriptor ID |
D009465
|
MeSH Number(s) |
D27.505.696.663.700
|
Concept/Terms |
Neuromuscular Effect- Neuromuscular Effect
- Effect, Neuromuscular
- Neuromuscular Effects
- Effects, Neuromuscular
|
Below are MeSH descriptors whose meaning is more general than "Neuromuscular Agents".
Below are MeSH descriptors whose meaning is more specific than "Neuromuscular Agents".
This graph shows the total number of publications written about "Neuromuscular Agents" by people in this website by year, and whether "Neuromuscular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 2 | 2 | 4 |
2004 | 3 | 0 | 3 |
2005 | 3 | 0 | 3 |
2008 | 2 | 0 | 2 |
2009 | 1 | 0 | 1 |
2011 | 1 | 1 | 2 |
2015 | 2 | 0 | 2 |
2016 | 1 | 0 | 1 |
2018 | 1 | 0 | 1 |
2019 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuromuscular Agents" by people in Profiles.
-
Crespi J, Bratbak D, Dodick DW, Matharu M, Jamtøy KA, Tronvik E. Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia. Headache. 2019 09; 59(8):1229-1239.
-
Blumenfeld AM, Tepper SJ, Robbins LD, Manack Adams A, Buse DC, Orejudos A, D Silberstein S. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. J Neurol Neurosurg Psychiatry. 2019 03; 90(3):353-360.
-
Chen TY, Garza I, Dodick DW, Robertson CE. The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients. Headache. 2018 Jul; 58(7):973-985.
-
Bratbak DF, Nordgård S, Stovner LJ, Linde M, Dodick DW, Aschehoug I, Folvik M, Tronvik E. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine. Cephalalgia. 2017 Apr; 37(4):356-364.
-
Hepp Z, Rosen NL, Gillard PG, Varon SF, Mathew N, Dodick DW. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database. Cephalalgia. 2016 Aug; 36(9):862-74.
-
Maasumi K, Thompson NR, Kriegler JS, Tepper SJ. Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine. Headache. 2015 Oct; 55(9):1218-24.
-
Aurora S, Diener HC, Dodick D. Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine. J Headache Pain. 2011 Apr; 12(2):137-8.
-
Marmura MJ, Silberstein SD. Current understanding and treatment of headache disorders: five new things. Neurology. 2011 Feb 15; 76(7 Suppl 2):S31-6.
-
Burstein R, Dodick D, Silberstein S. Migraine prophylaxis with botulinum toxin A is associated with perception of headache. Toxicon. 2009 Oct; 54(5):624-7.
-
Dusitanond P, Young W. Botulinum toxin type A's efficacy in nummular headache. Headache. 2008 Oct; 48(9):1379.